CD8A and ovarian carcinoma: For instance, an anti-CCR4 antibody mAb2-3 blocks Treg migration and stimulates IFNγ secretion by CD8+ T cells, eventually enhancing anticancer response in an experimental model bearing CCL22-secreting ovarian cancer cells (Chang et al., 2016).